Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint

Background: Alosetron is approved to treat women with severe IBS and diarrhea (IBS-D) who have failed standard therapy. In our study, we aimed to evaluate alosetron efficacy using new US Food and Drug Administration (FDA) endpoints and utilization in clinical practice. Methods: This prospective, ope...

Full description

Bibliographic Details
Main Authors: Brian E. Lacy, Jean Paul Nicandro, Emil Chuang, David L. Earnest
Format: Article
Language:English
Published: SAGE Publishing 2018-05-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284818771674

Internet

https://doi.org/10.1177/1756284818771674

Similar Items